Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2023 Jul 31;13:1257404. doi: 10.3389/fonc.2023.1257404

Corrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel

Mingyue Xia 1,, Shuyan Wang 1,, Yannan Qi 1,, Kaili Long 1, Enjie Li 1, Lingfeng He 1, Feiyan Pan 1, Zhigang Guo 1, Zhigang Hu 1,*
PMCID: PMC10425803  PMID: 37588092

Error in Figure/Table

In the published article, there was an error in Figure 2C as published. The panel in the bottom left of the figure was misused due to an error in the final assembly of Figure 2 . The corrected Figure 2C and its caption “Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel” appear below.

Figure 2.

Figure 2

Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel. (A) The down-regulation of OGT and O-GlcNAC by sh-OGT plasmids was detected by Western blotting. (B) CCK8 assays using OGT-KD stable cell lines treated with docetaxel in PC3 and DU145. Data are expressed as the mean ± standard deviation (SD), n=3 per group. (C) Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel. (D) Annexin V/PI staining and flow cytometry assay of control or OGT-KD cells with different drug treatments. (E) Western blot (WB) analysis of BAX and caspase-3 in control or OGT-KD PC3 and DU145 cells treated with various concentrations of docetaxel. All statistical data are presented as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES